Gastric cancer represents one of the most challenging malignancies in oncology, ranking fourth globally in cancer incidence and second in cancer-related mortality. In metastatic forms, the disease responds poorly to standard treatment modalities, with conventional therapy proving ineffective in 50-70% of patients.
Traditional treatment approaches for gastric cancer remain severely limited: surgical intervention is only viable in early-stage disease, radiation therapy is rarely applicable, and chemotherapy consists of merely a few protocols (FOLFOX, ECF, DCF) that typically cease functioning within months due to resistance development in most metastatic patients.
Consequently, this disease creates complex therapeutic scenarios requiring innovative approaches.
Innovative Immunotherapy Methods for Gastric Cancer Treatment
Modern immunotherapy approaches mobilize the body’s immune forces against cancer cells and demonstrate efficacy even where chemotherapy has proven powerless. Our comprehensive approach integrates multiple immunotherapeutic methods, creating synergy that proves particularly valuable for patients with disease recurrence or resistance to standard treatment.
Oncolytic Viruses in Gastric Cancer
Oncolytic viral therapy typically serves as the first-line treatment in our protocol for advanced gastric cancer. This method employs specially modified viruses that selectively target and destroy cancer cells while sparing healthy tissues. The therapeutic mechanism operates through several pathways:
- Direct destruction of gastric cancer cells through viral replication
- Release of tumor-derived substances that help immunity recognize cancer cells
- Transformation of immune-“invisible” tumors into “visible” ones
- Activation of the body’s immune system to combat the tumor
An intensive 14-day course of oncolytic therapy ensures maximum tumor exposure and immune system activation. When tumor location permits, the method is supplemented with direct administration of anti-cancer vaccines and photodynamic therapy.
The protocol demonstrates promising results in gastric cancer patients, frequently achieving tumor size reduction and creating optimal conditions for effective implementation of subsequent immunotherapy methods.
Checkpoint Inhibitor Therapy for Gastric Cancer Treatment
The second phase involves checkpoint inhibitor therapy, initiated 2-3 weeks following completion of the viral course. This precise timing ensures maximum immune system activity against cancer cells already “tagged” by the preceding viral therapy.
Low-Dose Checkpoint Inhibitor Immunotherapy
Our approach employs checkpoint inhibitors at reduced dosages, providing:
- Effective suppression of negative immune regulators PD-1/PD-L1 and CTLA-4
- Enhanced T-cell recognition of virus-marked tumor cells
- Significantly reduced autoimmune side effects compared to standard dosing protocols
- Extended treatment duration capability due to improved tolerability profiles
For patients with contraindications to standard checkpoint inhibitors or limited financial resources, we offer cytokine-mediated immunotherapy (CMI), providing comparable efficacy with enhanced accessibility and home administration options.
This sequential immunotherapy strategy first eliminates immunological barriers blocking anti-cancer responses, then maximally mobilizes the immune system against remaining tumor cells through targeted therapeutic methods.
Personalized Anti-Cancer Vaccines for Gastric Cancer
When cryopreserved gastric tumor tissue is available, we develop individualized anti-cancer vaccines using the patient’s own tumor material. Vaccine creation is also possible during planned surgical interventions when sufficient tumor tissue can be obtained for processing.
This personalized approach ensures:
- Development of therapeutic cancer vaccines targeting unique antigens of the patient’s gastric tumor
- Training the immune system to recognize and eliminate cancer cells
- Synergistic enhancement when combined with other immunotherapy methods
Anti-cancer vaccines represent one of the most promising directions in gastric cancer immunotherapy, providing precise targeting of each tumor’s distinctive molecular characteristics while effectively complementing our comprehensive treatment protocols.
ATACK Therapy: Treatment with Donor Lymphocytes
Our proprietary ATACK method (Allogeneic Targeted Activated Cancer Killer cells) utilizes specially prepared donor lymphocytes for targeted destruction of gastric cancer cells. These donor cells are intentionally distinct from the patient’s cells, enabling them to recognize and attack cancer cells as foreign entities.
Unlike attempts to restore a patient’s chemotherapy-weakened immune system, donor cells are inherently active and prepared for tumor combat. Maximum method efficacy is achieved following significant tumor mass reduction through other approaches, particularly when patients reach minimal residual disease (MRD) status.
Photodynamic Therapy for Gastric Cancer
In comprehensive gastric cancer treatment, we recommend, when feasible, supplementing immunotherapeutic methods with photodynamic therapy (PDT). This combined treatment strategy:
- Utilizes photosensitizers that selectively accumulate in gastric cancer cells and activate under specific light wavelengths
- Generates reactive oxygen species causing direct cytotoxic effects on tumor cells
- Stimulates localized inflammatory reactions and immune system activation
- Creates synergistic effects in combination with oncolytic viruses
Photodynamic therapy serves both direct tumor destruction and enhancement of subsequent treatment methods. Depending on primary tumor and metastatic locations, PDT can be administered systemically or locally for accessible tumor sites.
Who Is Suitable for This Treatment?
Our innovative gastric cancer treatment protocols may be appropriate for patients who:
- Have advanced adenocarcinoma of the stomach (metastatic gastric cancer)
- Have not achieved results from standard therapy or developed resistance to chemotherapy agents
- Have metastases whose localization permits direct administration of anti-cancer vaccines into tumor sites
- Possess specific molecular tumor markers that may respond to monoclonal antibody therapy
- Are in stable condition for international travel for treatment
How Does Treatment Proceed?
Treatment progresses in stages with a personalized approach for each patient:
- Initial Consultation: Personal consultation with Medical Director Professor Shimon Slavin via Zoom platform
- Treatment Planning: Development of personalized therapeutic protocols
- Oncolytic Viral Therapy: 14-day intensive course
- Subsequent Immunotherapy: Implementation of checkpoint inhibitor protocols or alternative cytokine-mediated therapy
- ATACK Therapy: Application of donor lymphocytes for elimination of remaining cancer cells and recurrence prevention
International Patient Support
- Assistance with logistics for international travel
- Coordination with local oncologists for follow-up care
- Online patient management with treatment outcome monitoring
How to Begin Treatment?
To determine if our immunotherapy program suits you:
- Complete the contact form on our website
- Send medical documents for review to [email protected]
- Schedule an online consultation with Professor Slavin via video conference
Professor Shimon Slavin personally analyzes each case and creates personalized treatment protocols. Our clinic serves patients who have not achieved results from standard therapy and require advanced gastric cancer immunotherapy methods.
The program provides access to experimental treatment methods unavailable in conventional medicine, offering new possibilities for patients with treatment-resistant forms of gastric cancer.
